| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1723719 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723730 | Distribution coefficient, logD of the compound at pH 7.4 | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723724 | Inhibition of CYP2C19 (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723732 | Oral bioavailability in human at 450 mg measured every 12 hrs | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723729 | Kinetic solubility of the compound | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723731 | Acid dissociation constant, pKa of the compound | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723727 | Inhibition of CYP3A4 (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723718 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723735 | Antibacterial activity against Neisseria gonorrhoeae assessed as reduction in bacterial growth | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723737 | Inhibition of human ERG up to 185 uM | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723722 | Intrinsic clearance in human hepatocytes assessed per 10^6 cells | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723728 | Protein binding in human plasma assessed as free fraction | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723714 | Antibacterial activity against Neisseria gonorrhoeae ATCC 49226 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723738 | Inhibition of human ERG at 100 uM relative to control | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723721 | Intrinsic clearance in human liver microsomes | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723723 | Inhibition of CYP1A2 (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723720 | Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723725 | Inhibition of CYP2C9 (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723715 | Antibacterial activity against fluoroquinolone-resistant Neisseria gonorrhoeae WHO L harboring multiple point mutations at DNA gyrase and topoisomerase IV and porB1b mutation assessed as reduction in bacterial growth by CLSI protocol based microdilution m | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723716 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723717 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723726 | Inhibition of CYP2D6 (unknown origin) | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| AID1723713 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth by CLSI protocol based microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
| Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |